New Stock Offerings - 济川药业 (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST亚振 (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - 中程退 (300208) has 7 trading days remaining until the last trading day[1] Delisting Notices - 退市锦港 (600190) has 7 trading days remaining until the last trading day[1] - 恒立退 (000622) has 4 trading days remaining until the last trading day[1] - 退市九有 (600462) has 3 trading days remaining until the last trading day[1] Abnormal Fluctuations - 北方长龙 (301357) reported severe abnormal fluctuations[1] - 浙江东日 (600113) reported abnormal fluctuations with an announcement time of June 28, 2025[1] - 诺德股份 (600110) reported abnormal fluctuations with an announcement time of June 27, 2025[1]

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

Group 1: Company Performance - Wanwei High-tech expects a net profit of 235 million to 265 million yuan for the first half of 2025, representing a year-on-year increase of 81.34% to 104.48% [1] - Jin Guan Electric has won bids for projects from Southern Power Grid and Guangxi Power Grid, with a total bid amount of approximately 42.81 million yuan, accounting for 5.76% of the company's 2024 revenue [2] - Ankai Bus reported a June vehicle sales increase of 37.88% year-on-year, with a total production of 814 vehicles, a 52.23% increase [4] - Daqin Railway's June cargo transport volume increased by 5.29% year-on-year, totaling 32.42 million tons [5] - Xianggang Technology anticipates a net profit of 75 million to 85 million yuan for the first half of 2025, a year-on-year increase of 410% to 478% [9] - Longxin General expects a net profit of 1.005 billion to 1.12 billion yuan for the first half of 2025, a year-on-year increase of 70.52% to 90.03% [10] - Le Xin Technology forecasts a net profit of 250 million to 270 million yuan for the first half of 2025, a year-on-year increase of 65% to 78% [11] - I-Le Furniture expects a net profit of 80 million to 99 million yuan for the first half of 2025, a year-on-year increase of 76.08% to 117.90% [13] - Shennong Group sold 219,000 pigs in June, generating sales revenue of 385 million yuan [14] - Guohuo Airlines anticipates a net profit of 1.187 billion to 1.267 billion yuan for the first half of 2025, a year-on-year increase of 78.13% to 90.14% [45] Group 2: Industry Developments - The electric power equipment industry is seeing increased project bids, as evidenced by Jin Guan Electric's recent contracts [2] - The automotive industry is experiencing growth, with Ankai Bus reporting significant increases in both production and sales [4] - The railway transportation sector is showing resilience with Daqin Railway's cargo transport volume growth [5] - The pharmaceutical industry is advancing with clinical trial approvals, such as Wanbang's WP107 oral solution for treating myasthenia gravis [6] - The packaging and printing industry is witnessing substantial profit growth, as indicated by Xianggang Technology's performance forecast [9] - The agricultural sector, particularly in pig farming, is maintaining steady sales figures, as shown by Shennong Group's sales data [14]

Core Insights - Hubei Jichuan Pharmaceutical announced that its subsidiary received a marketing license acceptance notice for its pediatric constipation granules, marking a significant development in the pediatric medicine sector [1][5]. Company Summary - Jichuan Pharmaceutical has invested approximately 51.41 million yuan in the development of pediatric constipation granules, which are based on a patented formula from a pediatrician at Capital Medical University [3]. - The company, established in 1997, holds a market value of 23.8 billion yuan and is recognized as a national high-tech enterprise and a key enterprise in the National Torch Program [6]. - In the first quarter of 2025, Jichuan reported a revenue of 1.525 billion yuan, a year-on-year decline of 36.51%, indicating pressure on its traditional business model and the urgent need for transformation [6]. Industry Summary - There are currently no similar prescription drugs for pediatric constipation available in China, highlighting a significant market gap that the pediatric constipation granules aim to fill [5]. - The pediatric medication market is characterized by a lack of innovative drugs, presenting a substantial opportunity for growth as health awareness increases and population demographics shift [6][7]. - The Chinese pharmaceutical industry is transitioning from a "follower" to a "runner" phase, with increasing support for traditional Chinese medicine innovation from government policies [7].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-050 湖北济川药业股份有限公司 关于收到药品注册申请受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，湖北济川药业股份有限公司（以下简称"公司"）全资子公司济川药 业集团有限公司（以下简称"济川有限"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的"小儿便通颗粒"申报上市许可的《受理通知书》，现 将情况公告如下： 二、 药品相关情况 小儿便通颗粒来源于陈永辉医生（现首都医科大学附属首都儿童医学中心， 中医科主任医师）行医多年的验方，其处方已申请专利；具有健脾和胃、行气导 滞的功效，用于小儿便秘，中医辨证属食积证者。根据国家药监局网站信息显示， 中国境内（不包括港澳台地区）暂无与其处方一致的药品上市或注册申报信息。 2025 年 7 月 8 日 三、 同类产品市场情况 目前，市场上可用于小儿便秘的同类产品主要用于其他疾病伴发的便秘症状， 临床尚无治疗小儿便秘的儿童专用中药创新药。该产品有望成为指导原则《小儿 便秘中药新药临床研 ...

Group 1 - The company has received a notice of acceptance for the registration application of "Children's Constipation Granules" from the National Medical Products Administration, marking the entry into the review stage for domestic production registration [1][2] - The product is derived from a patented formula by Dr. Chen Yonghui, aimed at treating pediatric constipation with specific efficacy in strengthening the spleen and stomach, and promoting digestion [1][2] - Currently, there are no similar registered products in China specifically for treating pediatric constipation, positioning this product as a potential first in its category following the release of new clinical guidelines in 2024 [2] Group 2 - The project has accumulated an investment of approximately 51.42 million yuan [2] - The acceptance of the registration application does not have a significant immediate impact on the company's current performance, but the sales post-launch may be subject to various market factors [2]

济川药业（600566）公告，全资子公司济川有限收到国家药监局签发的"小儿便通颗粒"申报上市许可的 《受理通知书》。该药品为中药1.1类，用于小儿便秘，处方已申请专利。目前，中国境内暂无与其处 方一致的药品上市或注册申报信息。该项目累计投入约5141.92万元。该产品有望成为首个用于小儿便 秘的中药1.1类儿童专用药。药品审评受理不会对本公司现阶段业绩产生重大影响。 ...

Core Viewpoint - The report outlines the offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd. by Cao Fei, which triggers a mandatory tender offer due to the increase in shareholding above 30% [19][24]. Group 1: Company Overview - Hubei Jichuan Pharmaceutical Co., Ltd. focuses on the research, production, and sales of pharmaceuticals, particularly in pediatrics, respiratory, digestive, and gynecological fields [7][8]. - The company has developed a core product matrix that includes pediatric medications and treatments for upper respiratory infections [8]. Group 2: Financial Data - The company's recent financial performance shows total revenue of 965,453.72 million yuan in 2023, with a net profit of 282,706.30 million yuan [9]. - The financial indicators for the first quarter of 2025 indicate a net profit of 44,129.27 million yuan, with a gross margin of 77.25% [10][11]. Group 3: Shareholding Structure - As of the report date, the total issued shares of the company are 921,704,160, with 99.35% being freely tradable [11]. - The report indicates that the acquirer, Cao Fei, does not currently hold shares in the company, while his associated parties hold significant stakes [18]. Group 4: Acquisition Details - The offer price for the tender is set at 24.85 yuan per share, which is based on the average price over the last 30 trading days prior to the announcement [20][21]. - The acquisition is structured to comply with legal requirements, ensuring that the company remains publicly listed post-acquisition [24]. Group 5: Independent Financial Advisor - Guojin Securities has been appointed as the independent financial advisor for the acquisition, confirming that the offer complies with relevant laws and regulations [24][23]. - The independent advisor's report supports the board's recommendation for shareholders to consider the offer based on the company's future prospects and market conditions [23][24].

湖北济川药业股份有限公司董事会 关于 曹飞 要约收购事宜 致全体股东的报告书 | 上市公司名称： | 湖北济川药业股份有限公司 | | --- | --- | | 股票上市地点： | 上海证券交易所 | | 股票简称： | 济川药业 | | 股票代码： | 600566.SH | 董事会报告签署日期：二零二五年七月 有关各方及联系方式 上市公司（被收购人）名称：湖北济川药业股份有限公司 联系地址：江苏省泰兴市大庆西路宝塔湾 联系人：曹伟 电话：0523-89719161 收购人名称：曹飞 收购人住所：上海市黄浦区**** 独立财务顾问名称：国金证券股份有限公司 独立财务顾问办公地址：上海市浦东新区芳甸路1088号23层 联系人：季文浩、吴卓 联系电话：021-68826021 1 董事会声明 一、本公司全体董事确信本报告书不存在任何虚假记载、误导性陈述或重大 遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 二、本公司全体董事已履行诚信义务，向股东所提出的建议是基于公司和全 体股东的整体利益客观审慎做出的。 三、本公司关联董事曹龙祥、曹飞、黄曲荣已回避对本报告书的审议表决， 本公司其他董事没有任何与本次 ...